Last reviewed · How we verify

Ecclock (SOFPIRONIUM BROMIDE)

Kaken Pharmaceutical · FDA-approved approved Small molecule Quality 55/100

Ecclock works by blocking the muscarinic acetylcholine receptor M3, which reduces sweat gland activity.

Ecclock (Sofpironium bromide) is a small molecule developed by Kaken Pharmaceutical and currently owned by Botanix Sb. It targets the muscarinic acetylcholine receptor M3, which is involved in sweat gland function. Ecclock is approved for the treatment of hyperhidrosis, a condition characterized by excessive sweating. The commercial status of Ecclock is patented, with no generic manufacturers available. Key safety considerations include its mechanism of action, which may have implications for patients with certain medical conditions.

At a glance

Generic nameSOFPIRONIUM BROMIDE
SponsorKaken Pharmaceutical
TargetMuscarinic acetylcholine receptor M3
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved
First approval2024

Mechanism of action

Imagine your nerves sending signals to your sweat glands to produce sweat. Ecclock blocks these signals, so your sweat glands don't get the message to produce as much sweat. This helps to reduce excessive sweating.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: